Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Teikoku Seiyaku Co., Ltd. (Japan) is developing a new Esflurbiprofen Hydrogel Patch (EFHP), a transdermal product containing 165 mg of the S-enantiomer of flurbiprofen (S-flurbiprofen) as its active pharmaceutical ingredient.
The present clinical trial will be conducted to characterise maximum observed systemic exposure of the newly developed EFHP (Test) vs. "Froben 100 mg" (Reference, containing 100 mg racemic flurbiprofen in a 1:1 ratio). Characterisation will be performed under steady state conditions in order to bridge the available safety information on the basis of the comparison of maximum observed systemic exposure by means of AUC0-24h,ss,P vs. AUC0-24,ss,T and Cmax,ss,P vs. Cmax,ss,T of S-flurbiprofen.
Full description
This single centre, open-label, randomised (order of treatments), balanced, multiple dose trial will be performed in a 2-period, 2-sequence-crossover design.
The Test Product (patch) will be applied once daily over 14 consecutive days, whereby each patch will remain applied for 24 h. Blood sampling will be performed after the 1st patch application over 24 h in order to characterise the single dose application and after the 14th patch application over 72 h in order to characterise pharmacokinetic parameters after multiple dosing including elimination phase. In between through values will be taken in the morning of specified study days to characterise steady-state built-up phase.
The Reference product will be administered after a light meal as single oral doses of 100 mg flurbiprofen three times daily (i.e. every 8 h) over 4 days. Blood sampling will be performed after the 10th tablet administration over 72 h in order to characterise pharmacokinetic parameters after multiple dosing including elimination phase. In between through values will be taken in the morning of study days 1 to 4 to characterise steady-state built-up phase.
The clinical trial will be performed as a cross-over investigation with intra-individual comparison, thus reducing variability of the pharmacokinetic parameters, which is supposed to be higher between subjects than within an individual subject.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Safety concerns
existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
existing or history of hypertension and/or heart failure
existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient
existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
history of gastrointestinal bleeding or perforation related to previous NSAID therapy
active, or history of, ulcerative colitis, Crohn's disease, peptic ulceration or gastrointestinal haemorrhage
existing metabolic, endocrine and/or immunologic diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient
diabetes mellitus
hyperlipidaemia (LDL > 160 mg/dL; HDL < 35 mg/dL; triglycerides > 200 mg/dL; cholesterol > 240 mg/dL)
history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
presence or history of acute or chronic diseases of the skin (e.g. atopy, neurodermatitis, contact allergy, eczema, psoriasis, vitiligo, melanoma, squamous cell carcinoma), any dermatological condition or skin sensitivity which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
existing or history of bronchial asthma
known allergic reactions (e.g. bronchospasm, rhinitis, angioedema, or urticaria) to the active ingredients used, to acetylsalicylic acid or other NSAIDs, or to constituents of the pharmaceutical preparations
history of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency
galactose intolerance or Lapp lactase deficiency
systolic blood pressure < 90 or > 139 mmHg
diastolic blood pressure < 60 or > 89 mmHg
heart rate < 50 bpm or > 90 bpm
QTc interval > 450 ms for men and > 470 ms for women
laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator
ASAT > 20% ULN, ALAT > 10% ULN, bilirubin > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL correspondents to of > 9 µmol/l ULN).
positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test or anti-HCV-test
symptoms of, or diagnosis of COVID-19 within the last 14 days prior to individual enrolment of the subject
contact to persons in risk regions as defined by the Robert Koch Institute within the last 14 days prior to individual enrolment of the subject
direct contact to persons with symptoms of, or diagnosis of COVID-19 within the last 14 days prior to individual enrolment of the subject Lack of suitability for the clinical trial
skin abnormality (e.g. tattoo (including tattoo that was removed), scar, sunburn or obvious difference in skin colour), open sores, or excessive hair at the application site
acute or chronic diseases which may interfere with the pharmacokinetics of the IMP
history of or current drug or alcohol dependence
positive alcohol or drug test at screening examination
regular intake of alcoholic food or beverages of >= 24 g pure ethanol for male or >= 12 g pure ethanol for female per day
subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
regular intake of caffeine containing food or beverages of >= 500 mg caffeine per day
blood donation or other blood loss of more than 400 ml within the last 2 months prior to individual enrolment of the subject
administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the subject
regular treatment with any systemically available medication (except hormonal contraceptives and hormonal replacement therapy, e.g. estrogens, L-thyroxine)
subjects, who report a frequent occurrence of migraine attacks
For female subjects with childbearing potential only:
positive pregnancy test at screening examination
pregnant or lactating women
female subjects who do not agree to apply highly effective contraceptive methods Administrative reasons
subjects suspected or known not to follow instructions
subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Primary purpose
Allocation
Interventional model
Masking
26 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal